ArticleBMC microbiology2025
Butyrate enhances gut dysbiosis by activating the cAMP/PKA/CREB signaling pathway to inhibit the progression of endometrial carcinoma.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGut microbiota may contribute to the progression and prognosis of extra-intestinal tumors. The relationship and mechanism between endometrial carcinoma (EC), the gut microbiota, and short-chain fatty acids (SCFAs) remain ambiguous. This study aimed to ascertain whether alterations in gut microbiota and SCFAs are associated with EC.
methodsWe assessed the gut microbiota composition and SCFAs concentrations in healthy volunteers and patients with EC using 16S ribosomal RNA and liquid chromatography–mass spectrometry, respectively. Subsequently, we investigated the impacts and associated mechanisms of the gut microbiota and SCFAs on cell phenotypes through cell experiments and comprehensive RNA sequencing.
resultsThe gut microbiota of patients with EC exhibited significant variation compared to that of healthy volunteers. At the phylum level, the abundance of Proteobacteria elevated in patients with EC relative to healthy individuals, whereas the abundance of Firmicutes and Bacteroidetes were diminished. Furthermore, the concentrations of acetic acid and butyric acid in the feces of patients were remarkably lower than those in healthy individuals. The fecal supernatant of patients with EC promoted the proliferation, invasion, and migration of EC cells and inhibited cell apoptosis. However, these effects were reversed following the addition of sodium butyrate (NaB) and sodium acetate. On further investigating the mechanisms underlying SCFAs involvement in regulating EC, RNA-seq analysis revealed enrichment of the cAMP/PKA/CREB signaling pathway in the EC supernatant plus NaB compared with EC. The tumor growth rate was accelerated in mice treated with the feces of patients with EC compared to untreated mice. Nevertheless, these effects were reversed by NaB gavage. NaB supplementation to EC feces increased Occludin and Claudin 1 protein expression in the colon of mice with EC, reshaped the structure of the mouse colon, decreased the interleukin (IL)-1β and tumor necrosis factor(TNF)-α levels, increased the IL-10 level, and exerted a protective role in EC progression.
conclusionsFeces of patients with EC revealed gut dysbiosis. Furthermore, fecal microbiota transplantation could promote tumor growth and disrupt the normal structure of the mouse colon; however, these effects were alleviated by butyrate, highlighting it as a viable therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.